The combination of organoid and CRISPER technology has been used to identify factors in CRC, such as the drivers of resistance to TGFβ mediated tumor restriction and suppressors in human CRC [266, 267], while colonic organoid has been used for evaluating the cytotoxicity of CAR [268]. Here, TGFB1 is linked to neoplasm.